Global Perspectives on Multiple Myeloma in 2021 and Beyond
Clinical experts from the US discuss global perspectives on current treatment strategies and emerging therapies, including MRD, IMiDs, proteasome inhibitors, and immunotherapy approaches.
Faculty Chair
Rafael Fonseca, MD
Mayo Clinic, Phoenix, AZ, US
Faculty Members
Leif Bergsagel, MD
Mayo Clinic, Scottsdale, AZ, USA
Irene Ghobrial, MD
Harvard Medical School, Dana-Farber Cancer Center, Boston, MA, USA
Craig Hofmeister, MD, MPH
Emory University School of Medicine, Atlanta, GA, USA
Nina Shah, MD
UCSF Health, San Francisco, CA, USA
Keith Stewart, MBChB
University Health Network, Toronto, Canada
Tom Martin, MD
University of California San Francisco Medical Center, USA
Sagar Lonial, MD
Winship Cancer Institute of Emory University, Atlanta, GA, USA
Peter Voorhees, MD
Levine Cancer Institute, Charlotte, NC
Faith Davies, , MD
NYU Langone , New York, NY
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Pursuing the Cure for Myeloma
- IMiDs – With Us Since 1999
- The Evolving Role of Proteasome Inhibitors (PIs)
- Monoclonal Anti-CD38
- CAR T Therapies for the Treatment of MM
- Bispecifics for the Treatment of MM
- Other Agents on the Horizon in MM and Moving the Needle Forward
